Navigation Links
Skinvisible Appoints Dr. George Korkos to Its Advisory Board
Date:10/26/2007

Dr. Korkos' Expertise to Help Build New Opportunities

LAS VEGAS, Oct. 26 /PRNewswire-FirstCall/ -- As part of its strategy to continue to expand its product pipeline and pharmaceutical contacts, Skinvisible, Inc. (OTC Bulletin Board: SKVI) http://www.skinvisible.com, the developers of Invisicare(R), a patented polymer delivery system for topical skincare products, today announced the appointment of George J. Korkos, M.D. to its Advisory Board. Dr. Korkos is a nationally renowned plastic and reconstructive surgeon and is also known for his business acumen.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO

http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

"We are pleased to have such a distinguished world-class plastic surgeon agree to contribute his medical and business expertise to Skinvisible as we continue to develop our polymer delivery technologies and new topical products for the global marketplace," said Mr. Terry Howlett, President / CEO of Skinvisible. "Dr. Korkos will be a great addition to our Board. He has the medical expertise, business experience, contacts and enthusiasm to assist us in bringing Skinvisible and our products in front of new companies, both in the medical/plastic surgery area and the investment community. He has ideas for new applications for our technology and will assist us in taking these products from concept to commercialization."

"I am pleased to be asked to serve on the Advisory Board of Skinvisible, Inc." said Dr. Korkos. "They have an exciting technology that I believe has many interesting applications in the medical field. The skincare industry is looking for new innovation to enhance their product lines and the Invisicare delivery technology does exactly that. I also like the fact that Skinvisible is dedicated to R&D and protecting their intellectual property at every turn; that's key in this industry."

Dr. Korkos received his degree from the Medical College of Wisconsin and did his plastic surgery residency at St. Louis University. He is currently the President of Plastic Surgery Associates in Milwaukee, Wisconsin and Blue Mound Surgery Center along with being an Associate Clinical Professor at the Medical College of Wisconsin. Recently Dr. Korkos was honored with the establishment of the first endowed chair at the Medical College of Wisconsin; The George J. Korkos Chair in Plastic Surgery. His business background is diverse. Along with sitting on Boards of emerging companies, Dr. Korkos has also served on the Board of a number of financial and investment institutions.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com

About Invisicare(R)

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007)


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. George Bush pledges 200 million dollars for AIDS relief
2. Arsenic May Have Been Responsible For The Madness Of King George III Of England
3. Study Unveils New Insight To The Madness Of King George III
4. Investigation into the Poor Hospital Facility That Led To the Death of George Cook
5. Georgetown University Heads Alternative Tobacco Project
6. WHO lifts HongKong advisory
7. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
8. Doctors Said – ‘Stop Pressurising NHS Advisory Bod’
9. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
10. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
11. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: